Fineotex Chemical Ltd Q1 FY27 Earnings Analysis
Published 24 May 2026 | Chemicals & Petrochemicals | Market Cap: ₹2.7K Cr
Price
₹33.2
Market Cap
₹2.7K Cr
P/E Ratio
27.6
Revenue Rank
Margin Rank
Earnings Summary
- Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. - Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon.
📊 Revenue & Sales Performance
Rank 1- Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. $90-100 million (Q4 annualized) to $200 million by 2028, accelerating from prior 2030 target (Page 6, 7). - Textiles business will continue organic growth but decrease in revenue percentage due to faster oilfield segment growth (Page 19-20). - Expansions like doubling capacity in Midland and increased R&D investment support growth (Page 18-20). - EBITDA margins targeted to improve to 18-20%, indicating operational leverage alongside revenue growth (Page 14, 10). Overall, Fineotex foresees robust growth driven by oilfield specialty chemicals and strategic acquisitions.
📈 Profitability & Margins
Rank 1- Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon. - Q4 FY26 sets a base with INR314 crore revenue, with international revenues rising to 70%. - EBITDA margin guidance: targeting 18%-20% blended EBITDA, achievable by FY27 or sooner. - Oil Specialty Chemicals now contribute ~55-60% of revenue—expected to grow faster than textiles. - CrudeChem (CCT) business expected to scale from ~$100 million annualized (Q4 run rate) to $200 million by 2028, with EBITDA margins near 15%. - EPS growth aligns with revenue and margin expansion; PAT for FY27 estimated in the range of INR175-185 crore. - Working capital cycle stable (~79 days), supporting healthy cash flows post-acquisition. - Strong focus on operational efficiencies and expanding specialty chemical portfolio for sustained profit growth.
🏗️ Capital Expenditure Plans
Yes- Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth. - Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments. - The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target. - There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S. and Middle East markets. - Fineotex has a subsidiary in UAE (Ras Al Khaimah) with plans to start a plant there, and remains open to acquisitions or tie-ups in the region. - The company remains cash-rich with no debt, enabling disciplined deployment of cash for strategic and organic growth investments.
💰 Fundraising & Capital Structure
No information- Fineotex Chemical Limited currently has no debt on its books and is described as a cash-rich company. - Recent acquisitions and capex investments (e.g., $7 million post-acquisition capex for CCT) have been funded internally. - There is no explicit mention of any upcoming or planned fundraising through debt or equity in the call transcript. - The company emphasizes disciplined cash deployment and prefers organic growth and selective inorganic acquisitions funded from internal accruals and cash reserves. - The management highlights a strong financial position enabling focus on growth opportunities without referencing any new equity or debt raising plans. - Any future developments about fundraising, if needed, would likely be communicated transparently to investors via stock exchange disclosures. In summary, Fineotex plans to fund growth from existing cash and internal resources, with no current indication of new debt or equity fundraising.
📋 Order Book & Pipeline
Yes- The Q4 of FY2025-26 is considered the baseline for future growth at CCT (CrudeChem). - The current order book at CCT is described as "too strong" and robust, indicating healthy pending orders. - Increasing market demand and strengthened customer trust are driving a growing order pipeline. - North American market expansion and new opportunities in the Middle East (e.g., Oman) suggest a rising order book. - With capacity enhancements and technology transfers, CCT expects to sustain and grow its order book significantly in the coming years.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Fineotex Chemical Ltd Q1 FY27 results?
- Fineotex targets a top-line growth of 3 to 4 times in the next 3-4 years, potentially reaching INR 3,000 crores (Page 16). - Q4 numbers are considered a base, with confidence in continued demand growth from existing customers; oilfield specialty chemicals contribute 55-60% of revenue (Page 19-20). - CCT (US acquisition) is expected to scale revenue from approx. - Fineotex expects significant top-line growth, potentially 3-5x in 3-4 years, driven by strong demand from large global customers like Shell and Exxon.
What is Fineotex Chemical Ltd share price analysis?
Fineotex Chemical Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 27.6 with a market cap of ₹2,676. Investors should review the full earnings analysis for detailed insights.
Is Fineotex Chemical Ltd planning capital expenditure?
- Fineotex Chemical is adding more capacities at its Midland (U.S.) facility with increased R&D team members and machinery investments to support growth. - Post-acquisition of CrudeChem (CCT), Fineotex has already invested around $7 million in capex and extended additional funds (~$7 million) for further investments. - The company plans to double capacity at CCT, aiming to scale business towards $200 million revenue by 2028, accelerated from earlier 2030 target. - There are ongoing discussions and plans for expansion, including inorganic growth opportunities, especially in the U.S.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
